Dr. Fishman on current unmet needs in kidney cancer

In this video, Mayer Fishman, MD, PhD, discusses some current unmet needs in the kidney cancer space. Fishman is a medical oncologist at Tampa General Hospital Cancer Institute in Tampa Bay, Florida.

Video Transcript:

Brain disease patients, that's still an unmet need. It's very ad hoc. So, when there's some brain disease, we're going to treat them. Then you just go to the trials, where every single trial excluded patients with brain disease. We'll do what we can. There's not a lot of empiric things on that. We see the pathways of PD-1 resistance being explored across oncology. Kidney cancer is not especially leading the way on that. Who should have LAG3? How does the VEGF blockade mediate a more permissive immune environment? What can you do to drill down on what's going on in the tumor before you make a decision to give immune therapy? We tried to do it early on with the PD-1 medicines. The effort is still ongoing. It's still an unmet need to have someone walk in and say, “Oh, we checked this. In clear cell kidney cancer, PD-L1, that's not going to do it. Tumor infiltration, not especially.” So, those are some of the things I’d like to see.

This transcription has been edited for clarity.